why us


  • Experienced in design
  • Experienced in operation

Our history and experience

10 years of hands-on experience in both design and operation

Serialization based T&T systems are mainly viewed as a record-keeping system achievable through minor upgrades in packaging lines and IT infrastructure enhancements. However, as the saying goes, “in theory, theory and practice are the same. In practice, they are not”.
Truth to the matter is, implementation of a comprehensive T&T system, though simple in principle, can prove to be a major challenge; And this is exactly where legislations and governmental initiatives -despite their strict timetables and tough stance on counterfeits - fall short as the knots and bolts of business procedures do not fall within the scope of law. That being said, delivering tangible benefits in this regard requires taking steps beyond imposing tougher controls and inspection requirements. The journey towards serialization is fraught with pitfalls and potential for error and without an accurate picture, supply chain stakeholders risk losses from otherwise preventable/manageable incidents.

One thing to take into consideration is that despite the individual elements of T&T systems being technically proven, implementing those same elements at such a great scale and granularity level gives rise to an overwhelming complexity which makes the system inherently susceptible to fracture. Consequently, having an infinitesimal detail overlooked in terms of design, test, or maintenance of the IT infrastructure could have severe implications for the workflow and lead to interoperability issues, downtimes and Supply disruptions.
That aside, once the system has launched the more intricate issue of adaptive challenges comes into play. Comparatively speaking, operation of a comprehensive T&T system is analogous to production line management in that a bottleneck in one of the sub-processes could adversely affect the whole system. Speaking in terms of track and trace systems, such bottlenecks are by no means rare occurrences. Lack of adequate and timely cooperation on the part of supply chain stake holders would predictably happen due the a multitude of reasons such as fear of disintermediation, insisting on keeping commercial data within one’s business domain, receiving insufficient instructions on how to interact with the system, etc. and failing to recognize such upcoming challenges beforehand as well as not having an appropriate risk evaluation and mitigation strategy in place, could effectively hinder the system from discharging its primary functions, Leaving little enthusiasm for anti-counterfeiting measures altogether.
Owing to our history in the field, we have come to recognize those challenges and fine-tuned our solution to address any possible adverse outcome. Our proven track record of success is not just a claim but delivered with evidence. SAMAN has been the sole commissioner of the IRFDA in the field of T&T for the Iranian pharmaceutical supply chain since 2008. Relying on our in-house designed software solutions we have provided the IT infrastructure that literally encompasses all stakeholders (i.e. pharmacists, wholesalers, Manufacturers, governmental organizations) in a single unified solution; supporting the nationwide operation for 10 consecutive years. Aside from the system design, managing the day-to-day operations of a comprehensive T&T system on a Scale Rivaled by few, has equipped us with best practice models and the required know-how for a seamless implementation of the system. Utilizing that experience, we could help you navigate technical and operational hurdles and accompany you through your serialization journey towards a successful end.

why us


  • Based on EPCIS
  • IDMP compliant

In compliance with globally accepted standards

designed based on GS1 standards

A study published in the “American Journal of Tropical Medicine and Hygiene” which had assessed both open and non-public pharmaceutical supply chain data sources with regards to falsified and counterfeit medicine found that for the period of 2009-2011 and among 169 countries, 127 had no reports of counterfeit incidence at all; meaning that countries have been mainly ignoring this problem. However, the landscape for the war against falsified medicine has changed noticeably during last few years. Governments around the world are increasingly enacting legislations to address the issue of counterfeit and falsified medicine and chief solution among those mandates is mass serialization. Undoubtedly having a comprehensive T&T system in place could yield tremendous benefits for every country.

That being said, the full potential of track and trace systems is only realized by mainstream adoption of a unified solution which reflects the global nature of pharmaceutical supply chains. Consequently, all fragmented endeavors throughout the globe are expected to eventually gravitate towards a solution which would foster interoperability and closer co-operation among states. In anticipation of said upcoming globalization it only makes sense to invest in a solution which is designed in accordance with the aforementioned trends. SAMAN’s T&T system is designed in full compliance with the widely endorsed GS1 standards including EPCIS and will continue to accommodate future upgrades of said standards.

why us


  • Flexible in design
  • Flexible in maintenance

Free from proprietary equipment

a flexible and adaptable solution

With the evolution of track and trace from a luxury to a must-have, companies are looking for solutions which are most cost-effective and yield the highest ROI on the investment that they will eventually be required to make. Implementation of Track and trace schemes is admittedly a costly undertaking which can run into millions; A great portion of which is attributed to the need for replacing and retrofitting the existing equipment in warehouses and packaging lines as a prerequisite to enable serialization . Recognizing such hurdles, we have incorporated a cost-centric mindset into our approach and designed Our Systems accordingly so to satisfy the legislator and address the cost related concerns of the pharma companies at the same time. This is achieved through a conceptual differentiation at the design level between core IT structures and integrators and hardware functions. Based on this approach, we offer robust yet flexible surveillance program enabling you to:

Source the required equipment from a wide range of OEMs to better manage costs; Have unrestricted access to parts and maintenance services and avoid downtimes; And have agility In the case of occasional upgrades or relocation of packaging lines.
We believe that our design approach would help minimize the burden of upgrade costs and accelerate the adoption trend among pharma companies.